New ultrasound could spot heart danger in cancer patients
NCT ID NCT07538544
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-phase study tests whether a special ultrasound with a targeted contrast agent (Sonazoid) can quickly diagnose heart inflammation caused by immune checkpoint inhibitor cancer drugs. About 30 adults who recently received these drugs and show signs of heart inflammation will be scanned. The goal is to see if this imaging method can accurately detect the condition, potentially leading to faster treatment and better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia
Charlottesville, Virginia, 22903, United States